Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon. Jump to: navigation, search. Biocon received marketing authorization for the drug from the Drugs Controller General of India (DCGI) in January 2013 and marketing within India commenced in August 2013. Jump up Biocon’s psoriasis drug, Itolizumab receives DCGI marketing authorization. The company’s total revenue for Q3 was up 23.63 per cent to Rs. 642.91 crore. During the quarter, the company got marketing authorisation from DCGI for Alzumab, a novel anti-CD6 biologic (Itolizumab) indicated for psoriasis and inked an option agreement with Bristol Myers Squibb for the novel oral Insulin program: IN 105. Biocon gets DCGI nod to market anti-psoriasis drug. Biocon has received marketing authorisation from the Drugs Controller General of India (DCGI) for Novel Biologic Itolizumab, an anti CD6 molecule, for the treatment of chronic plaque Psoriasis.
Biocon Launches Psoriasis Drug In India; To File IND Application With US FDA This Fiscal. That price has since fallen to 20 cents per day, and more than six million people in the developing world now receive treatment, up from little more than 2,000 in 2001.